Cargando…

Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial

INTRODUCTION: The optimal penetration of antiretroviral agents into central nervous system (CNS) may be a balance between providing adequate drug exposure to inhibit HIV-replication whilst avoiding concentrations associated with toxicities. METHODS: Cerebrospinal-fluid (CSF) exposure of efavirenz an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winston, Alan, and Puls, Rebekah, CSF Sub-study, group Encore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P050
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224808/ https://www.ncbi.nlm.nih.gov/pubmed/25394049 http://dx.doi.org/10.7448/IAS.17.4.19541

Ejemplares similares

The experience of people with cancer maintaining their physical activity with digital service delivery during COVID-19 – A service evaluation
por: Dewhurst, S., et al.
Publicado: (2022)

CARACTERÍSTICAS CLÍNICAS DOS PACIENTES COM SINTOMAS RESPIRATÓRIOS AGUDOS ATENDIDOS PELO SISTEMA DE TELEATENDIMENTO DE DIVINÓPOLIS/MG (TELECOVID)
por: Menezes, Aline Carrilho, et al.
Publicado: (2022)

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
por: Dickinson, Laura, et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study
por: Dickinson, L, et al.
Publicado: (2015)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

COMPETÊNCIAS DE ENFERMAGEM EM ATIVIDADES DE TESTAGEM RÁPIDA PARA COVID‐19
por: Maia, Jéssica Karen de Oliveira, et al.
Publicado: (2021)

OSSIFICAÇÃO HETEROTÓPICA NA COVID-19: RELATO DE CASO E REVISÃO DA LITERATURA
por: Danda, Guilherme José da Nóbrega
Publicado: (2022)

Santé mentale péri-natale en période de pandémie Covid-19 : programme d’accompagnement des parturientes, de dépistage et de protection
por: Ben Dhaou, G., et al.
Publicado: (2023)

Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study
por: Carey, Dianne
Publicado: (2014)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial
por: Xavier, Mariana S., et al.
Publicado: (2018)

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily
por: Seden, Kay, et al.
Publicado: (2018)

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
por: Wang, Tongtong, et al.
Publicado: (2023)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
por: Xu, Ling, et al.
Publicado: (2021)

Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
por: Dravid, Ameet, et al.
Publicado: (2022)

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
por: Schalkwijk, Stein, et al.
Publicado: (2018)

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
por: Xu, Ling, et al.
Publicado: (2021)

The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents
por: MacDonald, T M, et al.
Publicado: (2010)

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers
por: Jackson, AGA, et al.
Publicado: (2010)

Viro-immunological characterization of naïve patients with high cerebrospinal fluid (CSF) HIV RNA
por: Iannuzzi, Francesca, et al.
Publicado: (2014)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers in patients with plasma HIV RNA below 20 copies/mL
por: Calcagno, Andrea, et al.
Publicado: (2014)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
por: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
Publicado: (2010)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
por: Hill, Andrew, et al.
Publicado: (2014)

Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis
por: Babu, P Ravindra, et al.
Publicado: (2017)

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
por: Fleischmann, Roy, et al.
Publicado: (2008)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial
por: Cahn, Pedro, et al.
Publicado: (2018)

Single-tablet regimen is associated with reduced efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients
por: Fabbiani, M, et al.
Publicado: (2012)

The Fibrosis-4 index is associated with Intensive Care Unit (ICU) admission in middle-aged patients with COVID-19
por: Biliotti, E., et al.
Publicado: (2021)

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy
por: Davies, Olubanke, et al.
Publicado: (2014)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

On the Proper Treatment of the N400 and P600 in Language Comprehension
por: Brouwer, Harm, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j5ee2bubflb14g51fmc2d4ci7q